European Association of Urology guidelines on non–muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)
M Babjuk, M Burger, O Capoun, D Cohen… - European urology, 2022 - Elsevier
Abstract Context The European Association of Urology (EAU) has released an updated
version of the guidelines on non–muscle-invasive bladder cancer (NMIBC). Objective To …
version of the guidelines on non–muscle-invasive bladder cancer (NMIBC). Objective To …
Global trends in the epidemiology of bladder cancer: challenges for public health and clinical practice
LMC van Hoogstraten, A Vrieling… - Nature reviews Clinical …, 2023 - nature.com
Bladder cancer is among the ten most common cancers globally, causes considerable
morbidity and mortality and is, therefore, a substantial burden for health-care systems. The …
morbidity and mortality and is, therefore, a substantial burden for health-care systems. The …
International Bladder Cancer Group consensus statement on clinical trial design for patients with bacillus Calmette-Guérin–exposed high-risk non–muscle-invasive …
Context A large proportion of patients with non–muscle-invasive bladder cancer (NMIBC) fall
in the gap between bacillus Calmette-Guérin (BCG)-naïve and BCG-unresponsive disease …
in the gap between bacillus Calmette-Guérin (BCG)-naïve and BCG-unresponsive disease …
Sequential intravesical gemcitabine and docetaxel for bacillus Calmette-Guérin-naïve high-risk nonmuscle-invasive bladder cancer
IM McElree, RL Steinberg, AC Martin… - The Journal of …, 2022 - auajournals.org
Purpose: Bacillus Calmette-Guérin (BCG) is currently recommended as adjuvant therapy
following complete transurethral resection of bladder tumor for high-risk nonmuscle-invasive …
following complete transurethral resection of bladder tumor for high-risk nonmuscle-invasive …
[HTML][HTML] Elevated T-cell exhaustion and urinary tumor DNA levels are associated with Bacillus Calmette-Guérin failure in patients with non–muscle-invasive bladder …
T Strandgaard, SV Lindskrog, I Nordentoft… - European Urology, 2022 - Elsevier
Background The functional status of immune cells in the tumor microenvironment and tumor
characteristics may explain bacillus Calmette-Guérin (BCG) failure in high-risk non–muscle …
characteristics may explain bacillus Calmette-Guérin (BCG) failure in high-risk non–muscle …
Predictive clinico-pathological factors to identify BCG, unresponsive patients, after re-resection for T1 high grade non-muscle invasive bladder cancer
M Ferro, B Barone, F Crocetto, G Lucarelli… - … Oncology: Seminars and …, 2022 - Elsevier
Introduction Seventy-five percent of bladder cancers are non-muscle invasive. The treatment
strategy includes the transurethral resection of bladder tumor (TURB) followed by …
strategy includes the transurethral resection of bladder tumor (TURB) followed by …
Contemporary staging for muscle-invasive bladder cancer: accuracy and limitations
Context Bladder cancer prognosis and treatment are heavily dependent on accurate
staging. Traditional imaging and pathologic evaluation of transurethral resection (TUR) …
staging. Traditional imaging and pathologic evaluation of transurethral resection (TUR) …
[HTML][HTML] Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs
K Grabe-Heyne, C Henne, P Mariappan… - Frontiers in …, 2023 - frontiersin.org
Bladder cancer ranks among the most common cancers globally. At diagnosis, 75% of
patients have non-muscle-invasive bladder cancer (NMIBC). Patients with low-risk NMIBC …
patients have non-muscle-invasive bladder cancer (NMIBC). Patients with low-risk NMIBC …
Updated European Association of Urology (EAU) prognostic factor risk groups overestimate the risk of progression in patients with non–muscle-invasive bladder …
N Lobo, PJ Hensley, KK Bree… - European Urology …, 2022 - Elsevier
Abstract Background The 2021 European Association of Urology (EAU) guidelines contain
updated prognostic factor risk groups for non–muscle-invasive bladder cancer (NMIBC) …
updated prognostic factor risk groups for non–muscle-invasive bladder cancer (NMIBC) …
Hyperthermic mitomycin C in intermediate-risk non–muscle-invasive bladder cancer: results of the HIVEC-1 trial
JC Angulo, JL Álvarez-Ossorio… - European urology …, 2023 - Elsevier
Background Optimising therapeutic strategies of intermediate-risk non–muscle-invasive
bladder cancer (IR-NMIBC) is needed. Objective To compare recurrence-free survival (RFS) …
bladder cancer (IR-NMIBC) is needed. Objective To compare recurrence-free survival (RFS) …